Checkpoint Therapeutics, Inc. (CKPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...
Checkpoint Therapeutics (NASDAQ:CKPT) just reported results for the second quarter of 2024. Checkpoint Therapeutics reported earnings per share of -18 cents. This was above the analyst estimate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results